Seqens is an integrated global leader in pharmaceutical synthesis and specialty ingredients, delivering unrivalled market responsiveness and tailor-made solutions to their customers.
With 24 manufacturing sites and 3 R&D centers in Europe, North America and Asia, Seqens develops custom solutions and ingredients for the most demanding industries such as healthcare, electronics, cosmetics, food and homecare.
In December 2021, five years after their entry, Eurazeo, Merieux Equity Partners, Ardian and Eximium sold their stake in Seqens to SK Capital Partners, with a partial reinvestment of the proceeds in the company. Nov Santé managed by Eurazeo, also invested in Seqens. Bpifrance joined the project with a co-investing with SK Capital.
During this operation, Seqens completed a carve-out of their mining activity specialized in sodium-based mineral additives, which was renamed Humens, and where all the historical stakeholders remained in the capital to develop the business.
21 Chemin de la Sauvegarde - 69130 Ecully - FRANCE